BIODEGRADABLE NANOPARTICLES FOR SUBCUTANEOUS ADMINISTRATION OF GROWTH-HORMONE RELEASING-FACTOR (HGRF)

被引:38
作者
GAUTIER, JC
GRANGIER, JL
BARBIER, A
DUPONT, P
DUSSOSSOY, D
PASTOR, G
COUVREUR, P
机构
[1] UNIV PARIS 11,PHARM GALEN & BIOPHARM LAB,CNRS,URA 1218,RUE JB CLEMENT,F-92296 CHATENAY MALABRY,FRANCE
[2] SANOFI RECH,MONTPELLIER,FRANCE
关键词
POLYALKYLCYANOCRYANATE; NANOPARTICLE; GROWTH HORMONE RELEASING FACTOR (HGRF); PEPTIDE ADMINISTRATION;
D O I
10.1016/0168-3659(92)90140-M
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
This paper shows that biodegradable Poly Iso Hexyl Cyanoacrylate (PIHCA) nanoparticles are able to deliver Growth Hormone Releasing Factor (GRF) as a sustained-release system. Using nanoparticles, GRF plasma levels may be maintained constant for at least 24 h after the injection, after which GRF is still significantly present in the plasma, whereas, with free GRF, the maximum plasma concentration appears 2 min after the administration and no GRF can be detected after 100 min. The fact that nanoparticles are able to deliver sustained-release GRF after subcutaneous administration is consistent with the in vivo behaviour of radiolabelled nanoparticles as shown by autoradiography. In these experiments, nanoparticles are found to remain at the injection site for at least 24 h after subcutaneous administration. This was confirmed by transmission electron microscopy studies, which showed undegraded nanoparticles at the injection site after 24 h. Moreover, nanoparticles are able to protect GRF against enzymatic degradation. Analyses of the injection site 24 hours after subcutaneous administration have shown undegraded GRF in the nanoparticles. This fact could explain why GRF bioavailability was improved when administered in a nanoparticle formulation.
引用
收藏
页码:67 / 77
页数:11
相关论文
共 12 条
  • [1] SYSTEMIC DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS
    BANGA, AK
    CHIEN, YW
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1988, 48 (1-3) : 15 - 50
  • [2] NANOCAPSULES AS CARRIERS FOR ORAL PEPTIDE DELIVERY
    DAMGE, C
    MICHEL, C
    APRAHAMIAN, M
    COUVREUR, P
    DEVISSAGUET, JP
    [J]. JOURNAL OF CONTROLLED RELEASE, 1990, 13 (2-3) : 233 - 239
  • [3] NEW APPROACH FOR ORAL-ADMINISTRATION OF INSULIN WITH POLYALKYLCYANOACRYLATE NANOCAPSULES AS DRUG CARRIER
    DAMGE, C
    MICHEL, C
    APRAHAMIAN, M
    COUVREUR, P
    [J]. DIABETES, 1988, 37 (02) : 246 - 251
  • [4] DAPERGOLAS G, 1976, LANCET, V2, P824
  • [5] DUSSOSSOY D, 1991, INTERNAL REPORT SANO
  • [6] FLIER JS, 1985, INTRANASAL ADM INSUL, P217
  • [7] NASAL ABSORPTION OF INSULIN - ENHANCEMENT BY HYDROPHOBIC BILE-SALTS
    GORDON, GS
    MOSES, AC
    SILVER, RD
    FLIER, JS
    CAREY, MC
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (21) : 7419 - 7423
  • [8] NANOPARTICLES AS CARRIERS FOR GROWTH-HORMONE RELEASING-FACTOR
    GRANGIER, JL
    PUYGRENIER, M
    GAUTIER, JC
    COUVREUR, P
    [J]. JOURNAL OF CONTROLLED RELEASE, 1991, 15 (01) : 3 - 13
  • [9] PHARMACOKINETICS AND DISTRIBUTION OF A BIODEGRADABLE DRUG-CARRIER
    GRISLAIN, L
    COUVREUR, P
    LENAERTS, V
    ROLAND, M
    DEPREZDECAMPENEERE, D
    SPEISER, P
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1983, 15 (03) : 335 - 345
  • [10] PULSATILE VERSUS CONTINUOUS INTRAVENOUS ADMINISTRATION OF GROWTH-HORMONE (GH) IN GH-DEFICIENT PATIENTS - EFFECTS ON CIRCULATING INSULIN-LIKE GROWTH FACTOR-I AND METABOLIC INDEXES
    JORGENSEN, JOL
    MOLLER, N
    LAURITZEN, T
    CHRISTIANSEN, JS
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (06) : 1616 - 1623